<DOC>
	<DOCNO>NCT02286518</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability TAK-114 follow single multiple ascend oral dos healthy Japanese male participant .</brief_summary>
	<brief_title>TAK-114 Single- Multiple-Dose Phase 1 Study</brief_title>
	<detailed_description>This phase 1 , randomize , double-blind , placebo-controlled , single multiple oral dose study healthy Caucasian Japanese male participant . The study compose three part , Single-dose Ascending Part , Food Effect Part Multiple-dose Ascending Part . Single-dose Ascending Part Multiple-dose Ascending Part design randomize , double-blind open-label , placebo-controlled , sequential-cohort , ascend single multiple oral dose study TAK-114 match placebo . The Food Effect Part design randomize , open-label , 2-period crossover study single dose TAK-114 .</detailed_description>
	<criteria>Healthy Japanese participant : Must willing provide write informed consent investigator 's opinion able comply study protocol . Is age 20 45 year , inclusive . Weighs least 50 kilogram ( kg ) body mass index ( BMI ) 18.5 25.0 kilogram per square meter ( kg/m^2 ) . Healthy Caucasian participant : Must willing provide write informed consent investigator 's opinion able comply study protocol . Is age 20 45 year , inclusive ; Caucasian descent ( born Caucasian parent grandparent live outside original country le 5 year ) maintain original diet lifestyle . Weighs least 50 kg body mass index 18.5 30.0 kg/m2 . â€¢ Participants know hypersensitivity component formulation TAK114 herb medicine supplement relate Indigo naturalis .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>